Philip Theodore, Senior Vice President, [email protected] CNW Group 2015
Aeterna Zentaris Affirms Fundamental Strength of Business
View original source (CNW)COSCIENS Biopharma Inc. on 6ix
Story so far
Earlier from COSCIENS Biopharma
- Aeterna Zentaris Confirms No Corporate Developments
- Aeterna Zentaris Announces Exercise of Last Series B Warrants Covered by November 1, 2015 Agreement
- Aeterna Zentaris Announces First Patient Enrolled for Confirmatory Phase 3 Trial of Macrilen(TM) for the evaluation of AGHD
- Aeterna Zentaris Announces Details and Implementation of Share Consolidation to Regain NASDAQ Compliance
- Aeterna Zentaris Announces Shareholder Approval of Share Consolidation
Later from COSCIENS Biopharma
- CORRECTION FROM SOURCE: IIROC Trade Resumption - Aeterna Zentaris Inc.
- JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
- JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
- COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product
- COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents
Follow COSCIENS Biopharma into a list and get an email when it puts out news.
Follow COSCIENS Biopharma